Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine

NCT ID: NCT01745328

Last Updated: 2012-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Traditional Chinese Medicine (TCM) could be used to treat Recurrent urinary tract infection (RUTI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antibiotics and TCM are used to treat RUTI to evaluate treatment efficiencies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Urinary Tract Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

recurrent urinary tract infection antibiotics traditional chinese medicine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LVX-AMX

subject is treated with LAV-AMX, then followed by placebo.

Group Type ACTIVE_COMPARATOR

LVX-AMX

Intervention Type DRUG

Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.

LVX-AMX

Intervention Type DRUG

treatment with placebo from 2 to 4 weeks.

TCM treatment

subject is treated with TCM

Group Type ACTIVE_COMPARATOR

TCM

Intervention Type DRUG

Subject is treated with TCM for 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LVX-AMX

Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.

Intervention Type DRUG

TCM

Subject is treated with TCM for 4 weeks.

Intervention Type DRUG

LVX-AMX

treatment with placebo from 2 to 4 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Levofloxacin, 200mg bid, Amoxicillin, 500mg tid TCM formula consisted of 10 herbals placebo from 2 to 4 weeks.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* uncomplicated RUTI

Exclusion Criteria

* complicated RUTI
* other disease with urinary tract
* infection by pathogens other than bacteria
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Institute of Disease Control and Prevention

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zeliang Chen, Dr

Role: PRINCIPAL_INVESTIGATOR

Insititute of Disease Control and Prevention

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wangjing Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shiwei Liu, Dr

Role: CONTACT

Phone: 86-10-84739029

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shiwei Liu, Dr

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Liu SW, Guo J, Wu WK, Chen ZL, Zhang N. Treatment of Uncomplicated Recurrent Urinary Tract Infection with Chinese Medicine Formula: A Randomized Controlled Trial. Chin J Integr Med. 2019 Jan;25(1):16-22. doi: 10.1007/s11655-017-2960-4. Epub 2017 Jul 25.

Reference Type DERIVED
PMID: 28741061 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WJUTI

Identifier Type: -

Identifier Source: org_study_id